UBS analyst Michael Yee upgraded Inventiva (IVA) to Buy from Neutral with a price target of $12, up from $3, as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva, SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVA:
- Aligos Therapeutics initiated with a Buy at UBS
- Inventiva’s Shareholders’ Meeting Results in Key Resolutions Approval
- Positive Buy Rating for Inventiva Driven by Promising Phase 3 Trial and Strong Financial Position
- Inventiva price target lowered to $11 from $13 at Guggenheim
- Inventiva Secures $172.5M from Full Exercise of Underwriters’ Option